Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DTPA Clear all
Completed Phase 1Phase 2 Interventional

The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract

NCT06365762
View directory record Official record
Conditions
Age Related Cataracts
Interventions
EDTA Ophthalmic Solution 2.6%, EDTA Ophthalmic Solution 1.3%, Saline Solution (Placebo)
Drug
Lead sponsor
Livionex Inc.
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Francisco, California • Overland Park, Kansas • Lutherville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 19, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional Results available

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

NCT03029988
View directory record Official record
Conditions
Liver Metastases, Colorectal Carcinoma
Interventions
Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
Drug · Procedure
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

NCT00282295
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Boostrix®, Menactra™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
24
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

NCT02509598
View directory record Official record
Conditions
Rhabdomyosarcoma, Melanoma
Interventions
Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping
Drug · Procedure
Lead sponsor
Cardinal Health 414, LLC
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Jacksonville, Florida • Orlando, Florida • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 19, 2026, 4:20 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

NCT01118663
View directory record Official record
Conditions
Acetaminophen Overdose
Interventions
Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 19, 2026, 4:20 PM EDT
Terminated Phase 2 Interventional Results available

Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer

NCT04511026
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG), Neoprobe Gamma Detection System NPB11L(Model1102)
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 19, 2026, 4:20 PM EDT
Withdrawn Not applicable Interventional

Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?

NCT02371798
View directory record Official record
Conditions
Meniere Disease
Interventions
Gadopentetate dimeglumine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

NCT00874887
View directory record Official record
Conditions
Anti-biotic Resistance
Interventions
moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 19, 2026, 4:20 PM EDT
Completed No phase listed Observational

Sentinel Lymph Node Mapping Post-Injection Site Pain

NCT02065232
View directory record Official record
Conditions
Breast Cancer
Interventions
Tilmanocept, Sulfur Colloid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Anti-Cytokine Therapy for Hemodialysis InflammatION

NCT03141983
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Anakinra, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 19, 2026, 4:20 PM EDT
Active, not recruiting Phase 3 Interventional

Trial to Assess Chelation Therapy in Critical Limb Ischemia

NCT03982693
View directory record Official record
Conditions
Critical Limb Ischemia, Diabetes
Interventions
Edetate Disodium, Placebo
Drug · Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 4:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

NCT03332940
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
Interventions
Tc 99M Sulfur Colloid, Tc99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 1 Interventional

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

NCT02248051
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Anaheim, California • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

NCT02592551
View directory record Official record
Conditions
Mesothelioma
Interventions
MEDI4736, Tremelimumab, no other name
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)

NCT01902953
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Lymphoseek and VBD Sln dissection
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 19, 2026, 4:20 PM EDT
Recruiting Not applicable Interventional

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835
View directory record Official record
Conditions
Pediatric Intestinal Failure
Interventions
KiteLock 4% Sterile Catheter Lock Solution, Heparin Lock Solution
Device
Lead sponsor
SterileCare Inc.
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • Omaha, Nebraska • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Results available

Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer

NCT02287675
View directory record Official record
Conditions
Breast Cancer
Interventions
Lymphoseek, Sulfur Colloid
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Chelation Therapy (TACT)

NCT00044213
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
EDTA, EDTA Placebo, High Dose Vitamin, High Dose Vitamin Placebo
Drug · Dietary Supplement
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
73
States / cities
Little Rock, Arkansas • Danville, California • Fresno, California + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 2 Interventional Results available

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions
Testosterone cypionate, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 4:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Skin Barrier Function and Inflammation in Aging: The BIA Study

NCT06750653
View directory record Official record
Conditions
Inflammation, Skin Inflammation, Aging
Interventions
CeraVe Moisturizing Cream, Vaseline
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 19, 2026, 4:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse.

NCT07191262
View directory record Official record
Conditions
Extraction Sites After Removal and Bone Replacement Grafting at Extraction Sockets of Dentally Hopeless Single-rooted Teeth
Interventions
0.12% CHX and Essential Oil mouthrinse, 2.6% EDTA and 0.2% EDTA mouth rinse
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 19, 2026, 4:20 PM EDT